Clinical Trials Logo

Tricuspid Regurgitation clinical trials

View clinical trials related to Tricuspid Regurgitation.

Filter by:

NCT ID: NCT02644616 Completed - Clinical trials for Tricuspid Regurgitation

The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

Start date: November 2014
Phase: Phase 4
Study type: Interventional

The investigators research the early improvement of fluid retention and mid-term prognosis through the administration of tolvaptan for the patient with tricuspid regurgitation and right heart failure after left heart valves replacement.

NCT ID: NCT02502448 Completed - Clinical trials for Mitral Regurgitation

Acute Normovolemic Hemodilution on ROTEM in Cardiac Surgery

Start date: January 2016
Phase: N/A
Study type: Interventional

Impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established. Patients undergoing cardiac surgery employing moderate hypothermic CPB (n=40) are randomly allocated into one of two groups: in Group-ANH(n=20), ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C, ANH is not applied. After weaning from CPB, intergroup differences of INTEM, EXTEM, FIBTEM and APTEM profiles are analyzed. As a primary outcome, inter-group difference between maxiaml clot firmness of EXTEM will be determined at 10 min after ANH in Group-ANH and that at control.

NCT ID: NCT02098200 Completed - Clinical trials for Tricuspid Regurgitation

Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™

PREVENT
Start date: June 2013
Phase: Phase 1
Study type: Interventional

The TriCinch System™ is intended for percutaneous treatment of tricuspid regurgitation. It is a percutaneous catheter-based device designed for tricuspid valve repair in order to decrease effective cross-sectional area and relieve symptoms in patients with tricuspid valve regurgitation.

NCT ID: NCT01502462 Completed - Clinical trials for Tricuspid Regurgitation

Prospective Registry of Patients With Isolated Severe Tricuspid Regurgitation

Start date: February 2012
Phase:
Study type: Observational

Prospective registry for patients with severe isolated tricuspid regurgitation (TR) without significant left-sided valvular or myocardial diseases. Aim: To evaluate clinical course and prognostic factors of patients with severe isolated TR.

NCT ID: NCT01203137 Completed - Clinical trials for Tricuspid Regurgitation

Prognostic Value of Early Postoperative Right Ventricular Systolic Function in Patients With Isolated Severe Tricuspid Regurgitation

Start date: January 2009
Phase: N/A
Study type: Observational

Preoperative right ventricular end-systolic area (RV-ESA) and hemoglobin level were suggested as independent prognosticator for predicting long-term prognosis in patients with isolated severe TR undergoing corrective surgery We attempted to explore whether early postoperative echocardiography provides additional prognostic information on top of preoperative clinical and echocardiographic variables.

NCT ID: NCT01093001 Completed - Clinical trials for Left Ventricular Dysfunction

Tricuspid Regurgitation Study

Start date: May 2010
Phase: Phase 4
Study type: Interventional

The effect of cardiac pacing leads on tricuspid regurgitation is unclear. This study will determine whether using a smaller diameter leads and an alternate position in the ventricle, the proximal septum, will reduce tricuspid regurgitation than larger leads placed in the apex.

NCT ID: NCT00665301 Completed - Clinical trials for Congestive Heart Failure

Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000

Start date: March 2008
Phase: N/A
Study type: Observational

The purpose of this study is to compare cardiac output results obtained using the thermodilution push technique with the Pulmonary Arterial Catheter (PAC) to the predicted cardiac output results obtained from the non-invasive FloWave™ 1000 device.